At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 154 enrolled
Drug / intervention
Sugammadex +2 moredrug
Likely dose
Sugammadex 4 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Sugammadex Compared With Usual Care for Reversal of Neuromuscular Blockade Induced by Rocuronium on Incidence of Residual Blockade at PACU Entry
In Brief
A Phase 3 clinical trial evaluating Sugammadex, Neostigmine, and 1 other intervention for Surgical Procedures, Elective. Completed, enrolled 154 participants.
Detailed Summary
This study will compare the incidence of residual neuromuscular blockade in participants who undergo reversal of neuromuscular blockade with sugammadex compared to those who undergo reversal of neuromuscular blockade with usual care (neostigmine/glycopyrrolate).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSurgical Procedures, Elective
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartDec 2011
Primary CompletionOct 2012
Study CompletionNov 2012
TodayJul 2026
First PostedNov 24, 2011
Enrollment StartDec 2, 2011
Primary CompletionOct 26, 2012
Study CompletionNov 5, 2012
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 14.6 years ago
Interventions
Sugammadexdrug
sugammadex, intravenous (IV) bolus, 2 or 4 mg/kg depending on level of neuromuscular recovery
Neostigminedrug
neostigmine, per usual practice
Glycopyrrolatedrug
glycopyrrolate per usual practice